← Back to graph
Biomarker

C3 complement 24h urine

Selected indexed studies

  • Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. (Lancet, 2025) [PMID:41016405]
  • Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus. (Arthritis Res Ther, 2025) [PMID:40533865]
  • Telitacicept use in children with IgA vasculitis nephritis: preliminary observations. (Pediatr Nephrol, 2025) [PMID:40042623]

_Worker-drafted node — pending editorial review._

Connections

No connections recorded yet.

Sources

Local graph